A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

BACKGROUND: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronidase-zzxf], and Darzalex FASPRO [daratumumab and hy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Curr Ther Res Clin Exp
Päätekijät: Printz, Marie A., Dychter, Samuel S., DeNoia, Emanuel P., Harrigan, Rena, Sugarman, Barry J., Zepeda, Monica, Souratha, Jennifer, Kang, David W., Maneval, Daniel C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7490523/
https://ncbi.nlm.nih.gov/pubmed/32963641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.curtheres.2020.100604
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia